Matrix Laboratories

Premium

General

29 February, 2024

Grapevine: KKR mulls JB Pharma sale; Bharti eyes Del Monte JV exit

Private equity firm KKR & Co. is exploring options for a potential sale of its 53.8% controlling stake in Mumbai-based ......

Premium

Healthcare

03 January, 2024

Kotak's second special situations PE fund bankrolling big-ticket pharma acquisition

Kotak Alternate Asset Managers (previously Kotak Investment Advisors), the alternative investment arm of Kotak Group, which hit a first close of ......

Premium

Healthcare

04 September, 2017

Company watch: Concord Biotech eyes new opportunities after Quadria's backing

Biotechnologist Sudhir Vaid quit drugmaker Ranbaxy Laboratories Ltd exactly 20 years ago to start his entrepreneurial journey. The Ahmedabad-based biotechnology ......